Spots Global Cancer Trial Database for cervical carcinoma
Every month we try and update this database with for cervical carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma. | NCT03540407 | Cervical Carcin... Cervical Carcin... Cervical Carcin... Endometrial Ade... Endometrial Ade... Endometrial Ade... | Oncoxin-Viusid® Placebo | 18 Years - 80 Years | Catalysis SL | |
| Sentinel Lymph Node Biopsy Versus Pelvic Lymphadenectomy in Early-stage Cervical Cancer (PHENIX/CSEM 010) | NCT02642471 | Cervical Cancer Surgery Quality of Life | no systematic p... | 18 Years - 65 Years | Sun Yat-sen University | |
| Can Text Reminders Improve Uptake of Cervical Screening? | NCT02363088 | Cervical Carcin... Cervical Dyspla... | Neutral text me... Messenger text ... Social Norms A ... Social Norms B ... Framed Gain tex... Framed Loss tex... | 24 Years - 64 Years | Imperial College Healthcare NHS Trust | |
| Multilevel HPV Self-Testing Intervention for the Increase of Cervical Cancer Screening Among Women in Appalachia | NCT04411849 | Cervical Carcin... Human Papilloma... | Best Practice HPV Self-Collec... Informational I... Patient Navigat... | 30 Years - 64 Years | Ohio State University Comprehensive Cancer Center | |
| A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors | NCT05180799 | Solid Tumor, Ad... NSCLC Urothelial Carc... Gastric Cancer Small Cell Lung... Hepatocellular ... Cervical Carcin... Melanoma Renal Cell Carc... Carcinoma | BA3071 Nivolumab Pembrolizumab | 18 Years - | BioAtla, Inc. | |
| Evaluation of Ultraaccelerated High Dose Rate Intrauterine Interventional Radiotherapy | NCT06398938 | Locally Advance... | Interventional ... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Ixabepilone to Treat Cervical Cancer | NCT00924066 | Cervical Carcin... Cervical Adenoc... Cervical Adenos... Cervical Carcin... | Ixempra (Ixabep... | 18 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| I Vaccinate: Testing Multi-Level Interventions to Improve HPV Vaccination | NCT04452526 | Cervical Carcin... Human Papilloma... | Best Practice Educational Int... Questionnaire A... Reminder | 11 Years - | Ohio State University Comprehensive Cancer Center | |
| A Study of LY3435151 in Participants With Solid Tumors | NCT04099277 | Solid Tumor Triple-negative... Gastric Adenoca... Head and Neck S... Cervical Carcin... High Grade Sero... Hepatocellular ... Undifferentiate... Leiomyosarcoma | LY3435151 Pembrolizumab | 18 Years - | Eli Lilly and Company | |
| PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer | NCT05311566 | Cervical Carcin... Chemoradiothera... Anti-programmed... Immunotherapy Immune Checkpoi... Survival Outcom... Adverse Events Early Stage Cer... Locally Advance... | Camrelizumab pl... | 18 Years - | Peking Union Medical College Hospital | |
| HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Cervical Carcinoma | NCT02523365 | Cervical Carcin... | interventional ... | 18 Years - 80 Years | Fuda Cancer Hospital, Guangzhou | |
| The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer | NCT06283875 | Ovarian Cancer | 18 Years - 80 Years | Geneplus-Beijing Co. Ltd. | ||
| Clinical Study of Indocyanine Green Displaying Pelvic Nerve in Radical Operation of Cervical Cancer | NCT05087264 | Cervical Carcin... | Indocyanine gre... | 18 Years - 75 Years | Fifth Affiliated Hospital, Sun Yat-Sen University | |
| Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers | NCT04459273 | Bladder Carcino... Cervical Carcin... Cholangiocarcin... Hematopoietic a... Hepatocellular ... Malignant Adren... Malignant Brain... Malignant Pleur... Malignant Skin ... Malignant Solid... Malignant Testi... Malignant Thymu... Neuroendocrine ... Thyroid Gland C... Urothelial Carc... Cancer of Unkno... | Computed Tomogr... Gallium Ga 68 F... Positron Emissi... 18F-FDG | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer | NCT00404326 | Cervical Cancer | Hydralazine and... Punch biopsy of... | 18 Years - 70 Years | National Institute of Cancerología | |
| Barriers to Cervical Cancer Screening | NCT06284447 | Cervical Carcin... | Non-Interventio... | 21 Years - 65 Years | Mayo Clinic | |
| Evaluation of Ultraaccelerated High Dose Rate Intrauterine Interventional Radiotherapy | NCT06398938 | Locally Advance... | Interventional ... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Evaluation of Ultraaccelerated High Dose Rate Intrauterine Interventional Radiotherapy | NCT06398938 | Locally Advance... | Interventional ... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Pembrolizumab and Olaparib in Cervical Cancer Patients | NCT04483544 | Cervical Cancer Cervical Carcin... | pembrolizumab olaparib | 18 Years - | Baptist Health South Florida | |
| Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma | NCT03086681 | Cervical Carcin... | Endostar DDP | 18 Years - 65 Years | First Affiliated Hospital of Guangxi Medical University | |
| Intra-Operative Lymphatic Mapping in Patients With Invasive Carcinoma of the Cervix or Endometrial Carcinoma | NCT00595725 | Cervical Cancer Endometrial Can... Cervical Carcin... | Lymphatic Mappi... | - | Memorial Sloan Kettering Cancer Center | |
| Cervical Cancer Screening Intervention Among Korean American Women | NCT02594826 | Cervical Carcin... | Culturally appr... General health ... | 21 Years - | Fox Chase Cancer Center | |
| Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer | NCT05824468 | Cervical Cancer Cervical Carcin... | Zimberelimab Lenvatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer | NCT04230954 | Cervical Cancer Recurrent Cervi... Metastatic Cerv... Persistent Cerv... | Cabozantinib 40... Pembrolizumab 2... | 18 Years - | University of South Alabama | |
| Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer | NCT00404326 | Cervical Cancer | Hydralazine and... Punch biopsy of... | 18 Years - 70 Years | National Institute of Cancerología | |
| Adaptive Radiotherapy in Patients With Gynecological Tumors | NCT06230549 | Gynecological T... Adaptive Radiot... Radiation Curative Treatm... Optimization Adaptive Radiat... Image Guided Ra... Cervical Carcin... | Adaptive Radiot... | 18 Years - | University Hospital, Essen | |
| Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy | NCT04713618 | Anal Carcinoma Cervical Carcin... Endometrial Car... Malignant Pelvi... Rectal Carcinom... Vaginal Carcino... Vulvar Carcinom... | Pelvic Examinat... Survey | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors | NCT03372720 | Cervical Carcin... Dyspareunia Endometrial Car... Ovarian Carcino... Vaginal Carcino... Vaginal Dryness Vulvar Carcinom... | Laser Therapy Questionnaire A... Sham Interventi... | - | Ohio State University Comprehensive Cancer Center | |
| CATCH-UP Intervention in Increasing Cancer Screening and Prevention Care in Uninsured Patients at Community Health Centers | NCT02355262 | Breast Carcinom... Cervical Carcin... Colorectal Carc... Health Status U... Human Papilloma... Malignant Neopl... | Informational I... | 18 Years - | OHSU Knight Cancer Institute | |
| Neoadjuvant Chemotherapy + Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer | NCT02629718 | PFS OS Quality of Life | NACT (Paclitaxe... radical surgery | 18 Years - 65 Years | Sun Yat-sen University | |
| Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma | NCT00184093 | Uterine Cervica... | Gemcitabine | 18 Years - | University of Southern California | |
| A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | NCT05337735 | Microsatellite ... Peritoneal Meso... Extrapulmonary ... Neuroendocrine ... Cervical Carcin... Hodgkin's Lymph... Pleural Mesothe... Small Cell Lung... | XmAb20717 | 18 Years - | M.D. Anderson Cancer Center | |
| HPV16 E6 TCR T Cells for Cervical Carcinoma | NCT05357027 | Cervical Carcin... | TC-E202 cells IL-2 Fludarabine Cyclophosphamid... | 18 Years - 70 Years | TCRCure Biopharma Ltd. | |
| Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies | NCT00315861 | Ovarian Cancer Endometrial Can... Cervical Cancer Lung Cancer | pemetrexed topotecan | 18 Years - | SCRI Development Innovations, LLC | |
| Pembrolizumab and Olaparib in Cervical Cancer Patients | NCT04483544 | Cervical Cancer Cervical Carcin... | pembrolizumab olaparib | 18 Years - | Baptist Health South Florida | |
| Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma | NCT06241235 | Cervical Carcin... | ZG005 Powder fo... Paclitaxel Bevacizumab Cisplatin Carboplatin | 18 Years - 70 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer | NCT05824468 | Cervical Cancer Cervical Carcin... | Zimberelimab Lenvatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer | NCT04567771 | Cervical Carcin... Endometrial Car... Endometriosis Pelvic Inflamma... | Quality-of-Life... Questionnaire A... Radiation Thera... | 18 Years - | Mayo Clinic | |
| Fractional CO2 Laser Therapy for Survivors of Breast Malignancies | NCT03307044 | Breast Carcinom... Cancer Survivor Cervical Carcin... Dyspareunia Vaginal Dryness | Laser Therapy Questionnaire A... | - | Ohio State University Comprehensive Cancer Center | |
| Dose-finding Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and Bulky IIA Cervical Cancer | NCT00823186 | Cervical Cancer | Phyxol(Paclitax... | 35 Years - 70 Years | Chang Gung Memorial Hospital | |
| Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial | NCT05237947 | Cervical Carcin... Human Papilloma... | Diphtheria Toxo... Questionnaire A... Recombinant Hum... Recombinant Hum... | 18 Years - 30 Years | National Cancer Institute (NCI) | |
| Adaptive Radiotherapy in Patients With Gynecological Tumors | NCT06230549 | Gynecological T... Adaptive Radiot... Radiation Curative Treatm... Optimization Adaptive Radiat... Image Guided Ra... Cervical Carcin... | Adaptive Radiot... | 18 Years - | University Hospital, Essen | |
| Clinical and Pathological Characteristics as Prognostic Factors in Locally Advanced Cervical Cancer | NCT04537273 | Cervical Cancer | Descriptive and... | 18 Years - | National Institute of Cancerología | |
| A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | NCT05032040 | Ovarian Cancer Clear Cell Carc... Endometrial Can... Cervical Carcin... Metastatic Cast... | vudalimab | 18 Years - | Xencor, Inc. | |
| Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer | NCT05824468 | Cervical Cancer Cervical Carcin... | Zimberelimab Lenvatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers | NCT03345784 | Cervical Carcin... Endometrioid Ad... Malignant Femal... Recurrent Cervi... Stage I Uterine... Stage I Vaginal... Stage IA Uterin... Stage IB Cervic... Stage IB Uterin... Stage IB2 Cervi... Stage II Cervic... Stage II Uterin... Stage II Vagina... Stage IIA Cervi... Stage IIB Cervi... Stage III Cervi... Stage III Uteri... Stage III Vagin... Stage IIIA Cerv... Stage IIIA Uter... Stage IIIB Cerv... Stage IIIB Uter... Stage IIIC Uter... Vaginal Carcino... | Adavosertib Cisplatin External Beam R... | 18 Years - | National Cancer Institute (NCI) | |
| Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and Their Caregivers | NCT02412124 | Cervical Carcin... Ovarian Carcino... Uterine Corpus ... Vaginal Carcino... Vulvar Carcinom... | Supportive Care Quality-of-Life... Questionnaire A... | 19 Years - | City of Hope Medical Center | |
| Intra-Operative Lymphatic Mapping in Patients With Invasive Carcinoma of the Cervix or Endometrial Carcinoma | NCT00595725 | Cervical Cancer Endometrial Can... Cervical Carcin... | Lymphatic Mappi... | - | Memorial Sloan Kettering Cancer Center | |
| Support Program for Adoption of Cancer Screening Interventions at a Rural Community-Based Organization | NCT04208724 | Breast Carcinom... Cervical Carcin... Colorectal Carc... Malignant Solid... | Training Cancer Screenin... Survey Administ... | 18 Years - | Fred Hutchinson Cancer Center | |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | NCT02628067 | Advanced Cancer Anal Carcinoma Anal Cancer Biliary Cancer Cholangiocarcin... Bile Duct Cance... Neuroendocrine ... Carcinoid Tumor Endometrial Car... Endometrial Can... Cervical Carcin... Cervical Cancer Vulvar Carcinom... Vulvar Cancer Small Cell Lung... Small Cell Lung... Mesothelioma Thyroid Carcino... Thyroid Cancer Salivary Gland ... Salivary Gland ... Salivary Cancer Parotid Gland C... Advanced Solid ... Colorectal Carc... | pembrolizumab pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | NCT02628067 | Advanced Cancer Anal Carcinoma Anal Cancer Biliary Cancer Cholangiocarcin... Bile Duct Cance... Neuroendocrine ... Carcinoid Tumor Endometrial Car... Endometrial Can... Cervical Carcin... Cervical Cancer Vulvar Carcinom... Vulvar Cancer Small Cell Lung... Small Cell Lung... Mesothelioma Thyroid Carcino... Thyroid Cancer Salivary Gland ... Salivary Gland ... Salivary Cancer Parotid Gland C... Advanced Solid ... Colorectal Carc... | pembrolizumab pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies | NCT02025985 | Ovarian Carcino... Endometrial Car... Cervical Carcin... | Selinexor | 18 Years - | Karyopharm Therapeutics Inc | |
| A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression | NCT05325866 | Solid Tumors | Bemarituzumab | 18 Years - 99 Years | Amgen | |
| Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma | NCT06241235 | Cervical Carcin... | ZG005 Powder fo... Paclitaxel Bevacizumab Cisplatin Carboplatin | 18 Years - 70 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma | NCT03086681 | Cervical Carcin... | Endostar DDP | 18 Years - 65 Years | First Affiliated Hospital of Guangxi Medical University | |
| Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma | NCT05458869 | Cervical Carcin... Human Papilloma... | HPV Self-Collec... Interview Survey Administ... | 25 Years - | OHSU Knight Cancer Institute | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | NCT02465060 | Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ... | Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma | NCT01554410 | Cervical Carcin... | Intensity Modul... Cisplatin Gemcitabine | 18 Years - | University of California, San Diego | |
| Cervical Cytology - Do SMS Reminders Increase Participation in the Cervical Screening Programme? | NCT03975127 | Cervical Carcin... Cervical Dyspla... | SMS text | 22 Years - 29 Years | NHS Greater Glasgow and Clyde | |
| Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies | NCT00315861 | Ovarian Cancer Endometrial Can... Cervical Cancer Lung Cancer | pemetrexed topotecan | 18 Years - | SCRI Development Innovations, LLC | |
| ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss | NCT04065269 | Gynaecological ... | AZD6738 Olaparib | 18 Years - | Institute of Cancer Research, United Kingdom | |
| A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors | NCT05366478 | Melanoma Non Small Cell ... Cervical Carcin... | Autologous tumo... | 18 Years - | Suzhou BlueHorse Therapeutics Co., Ltd. | |
| Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies | NCT02578888 | Cervical Carcin... Ovarian Carcino... Primary Periton... Recurrent Cervi... Recurrent Ovari... Recurrent Uteri... Recurrent Vulva... Uterine Corpus ... Vulvar Carcinom... Peritoneal Neop... | Palliative Ther... Palliative Ther... | - | Albert Einstein College of Medicine | |
| Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | NCT03220009 | Cervical Carcin... Esophageal Carc... Mucosal Melanom... Mucosal Melanom... Oral Cavity Muc... Recurrent Melan... Stage II Vulvar... Stage III Vulva... Stage IIIA Vulv... Stage IIIB Vulv... Stage IIIC Vulv... Stage IV Oral C... Stage IV Vulvar... Stage IVA Oral ... Stage IVB Oral ... Stage IVC Oral ... Vaginal Carcino... | Conventional Su... Ipilimumab Laboratory Biom... Nivolumab Patient Observa... Radiation Thera... | 18 Years - | National Cancer Institute (NCI) | |
| Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer | NCT05511623 | Cervical Cancer | tislelizumab concurrent chem... | 18 Years - 70 Years | First Affiliated Hospital of Guangxi Medical University | |
| HPV Self-Test Intervention in Ohio Appalachia | NCT02460237 | Cervical Carcin... Human Papilloma... | Disease Screeni... Educational Int... Informational I... Laboratory Biom... Survey Administ... | 30 Years - 65 Years | Ohio State University Comprehensive Cancer Center | |
| I Vaccinate: Testing Multi-Level Interventions to Improve HPV Vaccination | NCT04452526 | Cervical Carcin... Human Papilloma... | Best Practice Educational Int... Questionnaire A... Reminder | 11 Years - | Ohio State University Comprehensive Cancer Center | |
| Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer | NCT03180294 | Breast Carcinom... Cervical Carcin... Ovarian Carcino... Postmenopausal Uterine Corpus ... Vaginal Carcino... Vulvar Carcinom... | Bupropion 150 m... Placebo | 18 Years - | NRG Oncology | |
| The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer | NCT06283875 | Ovarian Cancer | 18 Years - 80 Years | Geneplus-Beijing Co. Ltd. | ||
| Prognostic Value of Protein IMP3 Expression in Cervical Cancer | NCT05151159 | Cervical Carcin... | immunohistochem... | 20 Years - 60 Years | University of Mostar | |
| Dose-finding Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and Bulky IIA Cervical Cancer | NCT00823186 | Cervical Cancer | Phyxol(Paclitax... | 35 Years - 70 Years | Chang Gung Memorial Hospital | |
| Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study | NCT05180851 | Head and Neck C... Melanoma Breast Cancer Bladder Cancer Ovarian Carcino... Cervical Carcin... Lung Cancer | Recombinant L-I... | 18 Years - 75 Years | Shanghai Fengxian District Central Hospital | |
| A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | NCT05032040 | Ovarian Cancer Clear Cell Carc... Endometrial Can... Cervical Carcin... Metastatic Cast... | vudalimab | 18 Years - | Xencor, Inc. | |
| Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | NCT02584478 | Endometrial Car... Ovarian Carcino... Fallopian Tube ... Primary Periton... Cervical Carcin... | AL3818 Paclitaxel Pegylated Lipos... Topotecan Topotecan Carboplatin Paclitaxel AL3818 | 18 Years - | Advenchen Laboratories, LLC | |
| PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer | NCT05581121 | Cervical Carcin... Adenocarcinoma Adenosquamous C... | Standard treatm... Experimental ar... | 18 Years - | Institut Claudius Regaud | |
| Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer | NCT04567771 | Cervical Carcin... Endometrial Car... Endometriosis Pelvic Inflamma... | Quality-of-Life... Questionnaire A... Radiation Thera... | 18 Years - | Mayo Clinic | |
| Cervical Cancer Screening Intervention Among Korean American Women | NCT02594826 | Cervical Carcin... | Culturally appr... General health ... | 21 Years - | Fox Chase Cancer Center | |
| Support Program for Adoption of Cancer Screening Interventions at a Rural Community-Based Organization | NCT04208724 | Breast Carcinom... Cervical Carcin... Colorectal Carc... Malignant Solid... | Training Cancer Screenin... Survey Administ... | 18 Years - | Fred Hutchinson Cancer Center | |
| Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma | NCT05458869 | Cervical Carcin... Human Papilloma... | HPV Self-Collec... Interview Survey Administ... | 25 Years - | OHSU Knight Cancer Institute | |
| Multilevel HPV Self-Testing Intervention for the Increase of Cervical Cancer Screening Among Women in Appalachia | NCT04411849 | Cervical Carcin... Human Papilloma... | Best Practice HPV Self-Collec... Informational I... Patient Navigat... | 30 Years - 64 Years | Ohio State University Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
